$1.26 Billion is the total value of Bain Capital Life Sciences Investors, LLC's 34 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 15.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SWTX | SPRINGWORKS THERAPEUTICS INC | $299,444,000 | -2.3% | 4,831,307 | 0.0% | 23.75% | +24.9% | |
| DVAX | DYNAVAX TECHNOLOGIES CORP | $118,399,000 | -26.8% | 8,415,000 | 0.0% | 9.39% | -6.4% | |
| RAPID MICRO BIOSYSTEMS INC | $89,744,000 | -42.4% | 8,434,560 | 0.0% | 7.12% | -26.4% | ||
| ARQT | ARCUTIS BIOTHERAPEUTICS INC | $82,531,000 | -13.2% | 3,979,292 | 0.0% | 6.54% | +11.0% | |
| New | EQRX INC | $68,224,000 | – | 10,003,573 | +100.0% | 5.41% | – | |
| NUVALENT INC | $65,269,000 | -15.6% | 3,428,014 | 0.0% | 5.18% | +7.9% | ||
| CRNX | Buy | CRINETICS PHARMACEUTICALS IN | $57,664,000 | +63.1% | 2,029,701 | +20.8% | 4.57% | +108.5% |
| CCCC | Buy | C4 THERAPEUTICS INC | $52,879,000 | -27.9% | 1,642,210 | +0.0% | 4.19% | -7.9% |
| PHVS | PHARVARIS N V | $45,769,000 | -18.8% | 3,180,601 | 0.0% | 3.63% | +3.8% | |
| New | XILIO THERAPEUTICS INC | $44,887,000 | – | 2,805,413 | +100.0% | 3.56% | – | |
| ANNX | ANNEXON INC | $37,246,000 | -38.3% | 3,241,628 | 0.0% | 2.95% | -21.1% | |
| NRIX | Sell | NURIX THERAPEUTICS INC | $37,181,000 | -3.4% | 1,284,313 | -0.0% | 2.95% | +23.5% |
| MRSN | Buy | MERSANA THERAPEUTICS INC | $33,499,000 | -3.9% | 5,385,667 | +45.7% | 2.66% | +22.9% |
| APTX | APTINYX INC | $23,741,000 | +14.1% | 8,891,758 | 0.0% | 1.88% | +45.9% | |
| AVIR | Sell | ATEA PHARMACEUTICALS INC | $22,222,000 | -82.9% | 2,485,638 | -32.8% | 1.76% | -78.1% |
| TANGO THERAPEUTICS INC | $21,024,000 | -15.4% | 1,921,790 | 0.0% | 1.67% | +8.2% | ||
| SYRS | Buy | SYROS PHARMACEUTICALS INC | $20,422,000 | -21.0% | 6,264,420 | +8.3% | 1.62% | +1.0% |
| MARINUS PHARMACEUTICALS INC | $17,001,000 | +4.4% | 1,431,058 | 0.0% | 1.35% | +33.5% | ||
| SVRA | SAVARA INC | $14,412,000 | -10.1% | 11,622,598 | 0.0% | 1.14% | +14.9% | |
| Sell | ADAGIO THERAPEUTICS INC | $14,064,000 | -86.6% | 1,937,207 | -22.1% | 1.12% | -82.9% | |
| SLDB | SOLID BIOSCIENCES INC | $13,877,000 | -26.8% | 7,929,918 | 0.0% | 1.10% | -6.5% | |
| AGLE | AEGLEA BIOTHERAPEUTICS INC | $13,527,000 | -40.2% | 2,847,689 | 0.0% | 1.07% | -23.6% | |
| NAUT | NAUTILUS BIOTECHNOLOGY INC | $10,360,000 | -15.6% | 2,000,000 | 0.0% | 0.82% | +7.9% | |
| RACB | RESEARCH ALLIANCE CORP II | $9,770,000 | -0.8% | 1,000,000 | 0.0% | 0.78% | +26.8% | |
| ARYD | ARYA SCIENCES ACQU CORP IVcl a | $6,941,000 | -1.3% | 700,000 | 0.0% | 0.55% | +26.1% | |
| XFOR | Buy | X4 PHARMACEUTICALS INC | $6,610,000 | -41.0% | 2,886,542 | +36.2% | 0.52% | -24.7% |
| BLUE | BLUEBIRD BIO INC | $5,376,000 | -25.7% | 538,179 | 0.0% | 0.43% | -5.1% | |
| PANA | PANACEA ACQUISITION CORP II | $4,850,000 | -0.7% | 500,000 | 0.0% | 0.38% | +27.1% | |
| ARYA SCIENCES ACQUISITN CORP | $4,850,000 | -1.8% | 500,000 | 0.0% | 0.38% | +25.8% | ||
| BLSA | BCLS ACQUISITION CORP | $4,778,000 | -1.6% | 487,500 | 0.0% | 0.38% | +25.9% | |
| New | 2SEVENTY BIO INC | $4,598,000 | – | 179,393 | +100.0% | 0.36% | – | |
| OMEG | OMEGA ALPHA SPACcl a | $3,908,000 | +0.4% | 400,000 | 0.0% | 0.31% | +28.1% | |
| FLACU | FRAZIER LIFESCIENCES ACQU COunit 12/09/2025 | $2,976,000 | -1.1% | 300,000 | 0.0% | 0.24% | +26.2% | |
| JYAC | JIYA ACQUISITION CORP | $2,931,000 | +0.2% | 300,000 | 0.0% | 0.23% | +28.2% | |
| HLXA | Exit | HELIX ACQUISITION CORP | $0 | – | -250,000 | -100.0% | -0.15% | – |
| DRNA | Exit | DICERNA PHARMACEUTICALS INC | $0 | – | -3,080,237 | -100.0% | -3.85% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Bain Capital Life Sciences Partners, LP #1
- Bain Capital Life Sciences Fund, L.P. #2
- BC SW, LP #3
- Bain Capital Life Sciences Investors II, LLC #4
- Bain Capital Life Sciences Fund II, L.P. #5
- BCIP Life Sciences Associates, LP #6
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| APTINYX INC | 20 | Q1 2023 | 16.9% |
| SOLID BIOSCIENCES INC | 19 | Q3 2022 | 22.2% |
| SPRINGWORKS THERAPEUTICS INC | 17 | Q3 2023 | 41.8% |
| DICERNA PHARMACEUTICALS INC | 16 | Q3 2021 | 58.6% |
| DYNAVAX TECHNOLOGIES CORP. | 16 | Q3 2023 | 12.4% |
| SAVARA INC | 16 | Q3 2023 | 6.0% |
| X4 PHARMACEUTICALS INC | 16 | Q3 2023 | 3.2% |
| ARCUTIS BIOTHERAPEUTICS, INC. | 15 | Q3 2023 | 20.1% |
| MERSANA THERAPEUTICS, INC. | 14 | Q3 2023 | 8.4% |
| CRINETICS PHARMACEUTICALS, INC. | 14 | Q3 2023 | 5.4% |
View Bain Capital Life Sciences Investors, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-02-14 |
| 13F-HR | 2024-02-13 |
| 3 | 2024-02-07 |
| 4 | 2024-01-12 |
| 3 | 2023-12-29 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 3 | 2023-05-30 |
| 4 | 2023-05-30 |
| 13F-HR | 2023-05-15 |
View Bain Capital Life Sciences Investors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.